- Patients with advanced-stage NSCLC rank shortness of breath, bleeding, and fatigue as the adverse effects of chemotherapy they would most like to avoid.
Why this matters
- Coupling patient preferences and profiles of commonly used chemotherapy regimens could result in patient-centered treatment plans with better outcomes.
- Researchers studied the treatment choices of patients with advanced-stage NSCLC (n=232; 55.6% men; 95.3% white) based on medical records and interviews.
- Funding: Patient-Centered Outcomes Research Institute.
- Before and after experiencing chemotherapy, patients selected the adverse effect they would most like to avoid:
- Shortness of breath (before, 28.7%; after, 20.8%);
- Unusual or increased bleeding (20.9%; 14.3%);
- Decreased energy or excessive fatigue (11.9%; 25.6%);
- Dizziness (10.8%; 10.7%);
- A lot more expensive (8.4%; 9.5%);
- Jaundice (8.4%; 7.7%);
- More trips to clinic for treatment (7.2%; 7.1%);
- Numbness or tingling (1.8%; 1.2%); and
- Brittle nails (1.8%; 2.9%).
- Study data are not publicly available to protect patient confidentiality.
- Checkpoint inhibitors were not an approved first-line treatment during the study.
- Study results are limited to patients with advanced NSCLC.